CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY DEFICIT - USD ($)	Series A Preferred Stocks [Member]	Series B Preferred Stocks [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019			$ 7,422	$ 6,794,612	$ (8,496,088)	$ (1,694,054)
Beginning balance, shares at Dec. 31, 2019	75	75	74,225,141
Stock based compensation				1,722,599		1,722,599
Issuance of common stock for acquisition of intellectual property			$ 103	283,148		283,251
Issuance of common stock for acquisition of intellectual property, shares			1,025,000
Issuance of common stock for conversion of notes payable and accrued interest			$ 57	119,675		119,732
Issuance of common stock for conversion of notes payable and accrued interest, shares			570,767
Issuance of common stock for services			$ 185	844,523		844,708
Issuance of common stock for services, shares			1,850,000
Reduction of derivative liability				66,387		66,387
Net loss					(4,537,275)	(4,537,275)
Ending balance, value at Dec. 31, 2020			$ 7,767	9,830,944	(13,033,363)	(3,194,652)
Ending balance, shares at Dec. 31, 2020	75	75	77,670,908
Stock based compensation				1,351,751		1,351,751
Issuance of common stock for cash			$ 778	832,949		833,727
Issuance of common stock for cash, shares			7,768,188
Issuance of common stock for conversion of notes payable and accrued interest			$ 199	122,639		122,838
Issuance of common stock for conversion of notes payable and accrued interest, shares			2,009,155
Issuance of common stock for services			$ 53	105,242		$ 105,295
Issuance of common stock for services, shares			525,000			3,612,308
Issuance of common stock for in lieu of deferred compensation			$ 257	179,743		$ 180,000
Issuance of common stock for in lieu of deferred compensation, shares			2,567,308
Issuance of common stock due to settlement of accrued expenses			$ 52	103,948		104,000
Issuance of common stock due to settlement of accrued expenses, shares			520,000
Reduction of derivative liability due to conversions				68,072		68,072
Reduction of derivative liability						68,072
Net loss					(3,557,786)	(3,557,786)
Ending balance, value at Dec. 31, 2021			$ 9,106	$ 12,595,288	$ (16,591,149)	$ (3,986,755)
Ending balance, shares at Dec. 31, 2021	75	75	91,060,559

NEUROPATHIX, INC. 10-K